Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Company Overview

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Key Stats

• Today's Range: $0.53 to $0.56
• 50-Day Range: $0.43 to $0.81
• 52-Week Range: $0.30 to $3.18
• Volume: 1.90 million shs
• Average Volume: 9.01 million shs
• Market Capitalization: $126.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Moderate Buy

Sangamo Therapeutics Stock Analysis - MarketRank™

Sangamo Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 541st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sangamo Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sangamo Therapeutics has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.48% of the float of Sangamo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sangamo Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sangamo Therapeutics has recently decreased by 17.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sangamo Therapeutics does not currently pay a dividend.

Dividend Growth

Sangamo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.48% of the float of Sangamo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sangamo Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sangamo Therapeutics has recently decreased by 17.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.53

News Sentiment

Sangamo Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Sangamo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

10 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Sangamo Therapeutics is held by insiders.

Percentage Held by Institutions

56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGMO Stock Analysis - Frequently Asked Questions

How have SGMO shares performed this year?

Sangamo Therapeutics' stock was trading at $1.02 at the beginning of 2025. Since then, SGMO shares have decreased by 46.9% and is now trading at $0.5412.
View the best growth stocks for 2025 here.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its earnings results on Monday, May, 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company earned $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative trailing twelve-month return on equity of 345.98%.
Read the conference call transcript.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), abrdn Asia-Pacific Income Fund (FAX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGMO
• CIK: 1001233
• Web: www.sangamo.com
• Phone: (510) 970-6000
• Fax: 510-236-8951
• Employees: 480
• Year Founded: 1995

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $10.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +731.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.94 million
• Net Margins: -124.61%
• Pretax Margin: -124.84%
• Return on Equity: -345.98%
• Return on Assets: -79.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.76
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $57.80 million
• Price / Sales: 2.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 4.92

Miscellaneous

• Outstanding Shares: 233,170,000
• Free Float: 223,607,000
• Market Cap: $126.12 million
• Optionable: Optionable
• Beta: 1.20